RE-MODEL and RE-NOVATE : Total VTE and All-cause Mortality

Slides:

Advertisements

Similar presentations

Dose Escalating Safety Study of a New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, in Patients Undergoing Total Hip Replacement: BISTRO I Eriksson.

Advertisements

A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.

Georges Ghanem MD, FESC, FACC Associate Professor, Chief of Cardiology UMC-RH/LAU-SOM Beirut, Lebanon.

Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) Adapted from Jones et al. SABCS 2008, abstract /477169/465253/454771/ /4146.

Venous thromboembolism –

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Cardiovascular Complications After Joint Replacement Surgery: A Crossroad in Anticoagulation Vincent D. Pellegrini Jr, MD Professor and Chair Department.

Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Rivaroxaban for Prevention of Venous Thromboembolism After Total Knee Arthroplasty: Impact on Healthcare Costs Based on the RECORD3 Study Kwong L, Lees.

A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

The Risk of Cancer Following Total Hip or Knee Arthroplasty by Ravi Tharani, Frederick J. Dorey, and Thomas P. Schmalzried J Bone Joint Surg Am Volume.

Dabigatran Etexilate is Effective and Safe for the Extended Prevention of Venous Thromboembolism Following Total Hip Replacement Eriksson BI, Dahl OE,

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:

SANOFI-SYNTHELABOARIXTRA ® 1 ARIXTRA ® (fondaparinux sodium) in the prevention of venous thromboembolism after hip replacement surgery KA Bauer, BI Eriksson,

ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:

Oral Rivaroxaban Compared with Subcutaneous Enoxaparin for Extended Thromboprophylaxis After Total Hip Arthroplasty: The RECORD1 Trial Eriksson BI, Borris.

Oral, Direct Factor Xa Inhibition with Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip Replacement Eriksson BI, Borris L, Dahl.

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Use of Inhaled Corticosteroids and the Risk.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.

Thrombosis.TV Breaking Update: Betrixaban Approved by the FDA

Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LEADER trial: Primary Outcome

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

SAVE: Risk of total mortality associated with reduced kidney function

Relative Risk of Events by CHA2DS2-VASc Score

Association between highest tertile for homocysteine and mortality

ASCOT-BPLA: Primary and secondary end points

Relative risk of major events with atenolol vs placebo

Use of Targeted Temperature Management After Out-of-hospital Cardiac Arrest: A Meta- Analysis of Randomized Controlled Trials Ahmed Mahmoud, MD, Islam.

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

Health ABC: Mortality risk by quintile of cystatin C

Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non–Vitamin K Antagonist Oral Anticoagulants Matthew R.

APEX: Primary Efficacy and Safety Results

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Database-specific risk of ventricular arrhythmia associated with current use of azithromycin compared with current use of amoxicillin (2-stage random-effects.

Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

David J.A. Jenkins et al. JACC 2018;71:

Yousef Rezaei, MD American Journal of Kidney Diseases

Cystatin C levels and risk of death from all causes

Mintu P. Turakhia et al. JACEP 2016;2:

Probability of major bleeding event and ischaemic stroke/SEE versus trough plasma concentration of dabigatran. Calculated for a 72-year-old male patient.

Prabhat Kumar et al. JACEP 2016;j.jacep

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Patient characteristics: American vs Canadian transplant patients

Berger JS, et al. JAMA 2009;301:

Probability of major bleeding event and ischaemic stroke/SEE versus trough plasma concentration of dabigatran. Calculated for a 72-year-old male patient.

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Calibration plots for the clinical GDRS in the EPIC-Potsdam study (A) and the GNHIES98 cohort (B). Predicted risks were determined using score points,

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Davide Capodanno et al. JCIN 2009;2:

Absolute mortality difference Change in LVEF from baseline

Increase in adults treated at children's hospitals, 1999–2012, according to age group. Increase in adults treated at children's hospitals, 1999–2012, according.

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

Immunosuppression significantly reduced all-cause mortality or risk of ESRD (A) and significantly increased complete or partial remission (B) at the end.

Christian Madelaire et al. JCHF 2018;6:

Increase of physical activity over time associated with lower HF risk

Figure 7. Subgroup analysis according to the study design and support of CPB during CABG. The study design and support of CPB did not affect the results.

Gianluigi Savarese et al. JCHF 2016;4:

Balancing bleeding in brain metastases

Presentation transcript:

RE-MODEL and RE-NOVATE : Total VTE and All-cause Mortality Trials Dabigatran etexilate 220 mg dabigatran etexilate 150 mg enoxaparin 40 mg RE-NOVATE (Hip) N= 880 874 897 Incidence (%) 53 (6.0) 75 (8.6) 60 (6.7) Risk ratio over enoxaparin 0.9 1.28 95 % Confidence Interval (CI) 0.63-1.29 0.93-1.78 RE-MODEL (Knee) 503 526 512 183 (36.4) 213 (40.5) 193 (37.7) 0.97 1.07 0.82-1.13 0.92-1.25 Adapted from Dahl et al. EHA 2008.

RE-MODEL and RE-NOVATE : Incidence and Severity of Major Bleeding Dabigatran etexilate 220 mg dabigatran etexilate 150 mg enoxaparin 40 mg Treated 1 825 (100.0) 1 866 (100.0) 1 848 (100.0) Major bleeding 33 (1.8) 24 (1.3) 27 (1.5) Any bleeding 251 (13.8) 258 (13.8) 247 (13.4) Adapted from Dahl et al. EHA 2008.